Close Menu

NEW YORK – Suzhou, China-based Alphamab Oncology today announced plans to partner with Sanofi China to study the investigational agent KN026 with the chemotherapy agent docetaxel.

The drug combination will be evaluated as a treatment for patients with HER2-positive breast cancer. Under the terms of the partnership, Alphamab's wholly owned subsidiary Jiangsu Alphamed and Sanofi China will jointly evaluate the drug combination, and Sanofi will be granted an exclusivity period to negotiate the in-licensing of KN026, contingent on the agent achieving certain clinical milestones.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.